Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product will be marketed by Dr. Reddy's
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Subscribe To Our Newsletter & Stay Updated
